Bioatla, Inc. (BCAB) Stock Price & Analysis

Bioatla, Inc. (BCAB) fell 2.60% to USD 3.37 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.

BCAB last closed at USD 3.46; the session ranged USD 3.2–3.48 on volume of 41,414 shares. Market capitalization is $5.59M, with a 52-week range of USD 3.12–71.5 (NCM). Source: Nexqual, July 25, 2026 at 02:21 UTC.

Key Statistics (as of July 25, 2026 at 02:21 UTC)

Technical Analysis (BCAB)

Nexqual's technical model rates BCAB "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.

Analyst Ratings (BCAB)

Wall Street analysts rate BCAB "None", per Nexqual as of July 25, 2026 at 02:21 UTC.

Earnings (BCAB)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 02:21 UTC.

Financials & Fundamentals (BCAB)

Source: Nexqual, July 25, 2026 at 02:21 UTC.

Financial Health Score (BCAB)

Nexqual rates Bioatla, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 02:21 UTC.

Ownership (BCAB)

Source: Nexqual, July 25, 2026 at 02:21 UTC.

Leadership (BCAB)

Bioatla, Inc. is led by Jay M. Short (age 67), Co-Founder, CEO & Chairman, per Nexqual as of July 25, 2026 at 02:21 UTC.

Major Backers & Investors (BCAB)

Notable institutional backers of Bioatla, Inc. include Marshall Wace LLP, Acorn Capital Advisors, LLC , Millennium Management, according to Nexqual as of July 25, 2026 at 02:21 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 02:21 UTC.

From Bioatla, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• Through the use of our proprietary technology, we have developed CAB antibodies which we believe have specificity for tumors, while avoiding binding to the same antigen target expressed on many normal tissues.
• We have received guidance from FDA that 1.8 mg/kg of ozuriftamab vedotin delivered every other week satisfies dose optimization requirements. o In connection with the strategic process, we are re-evaluating the timing and scope of our clinical development programs, including the appropriate timeline and pacing of additional enrollment in the Phase 1 study of BA3182 and the timeline to commence a Phase 3 study for ozuriftamab vedotin. • Continue to leverage our CAB platform.
• Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
• Our conditionally active biologics ("CAB" or "CABs") capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target.

Partnerships

• Amended and Restated Exclusive Rights Agreement with Himalaya Therapeutics SEZC In January 2020, we entered into an Amended and Restated Exclusive Rights Agreement with Himalaya Therapeutics SEZC.
• Investment Agreement with Inversagen AI On December 30, 2025, we entered into an Investment Agreement (the "Investment Agreement") with Inversagen AI, LLC, a Delaware limited liability company ("Inversagen AI"), and Alliance International Resources Corp., a Nevada corporation ("AIRC").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.